EMA Says Yes To Eight New Medicines, Holds Fire On Others
Executive Summary
The European Medicines Agency today announced the new medicines it believes should be approved for use across the EU.
You may also be interested in...
England’s NICE Backs Ultragenx’s Rare Disease Drug Evkeeza After Applying Anti-Discrimination Principles
NICE, the health technology assessment body for England and Wales, looked beyond cost-effectiveness measures alone in its appraisal of Ultragenx’s rare disease drug Evkeeza, resulting in a positive reimbursement recommendation for all eligible patients.
Deal Watch: J&J Begins 2022 With Trio Of Technology Alliances
Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.
BeiGene’s Brukinsa Among Nine Drugs To Win EU Marketing Thumbs Up
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.